That is, even big pharma will be less likely to "go it alone" -- when banking on a misfire in a competitor's class of next-gen candidates. [And yes -- I suppose I should admit it, out loud -- I am saying that Pfizer may now view its ertugliflozin R&D program as no longer "first in the class" of the next gen candidates for type 2 diabetes management.]
Even so, this could be pretty good news for Merck's Januvia® franchise, as it might extend the life of that agent -- and stave off the next gen competition for a year or two.
In any event, here is a bit of this morning's Reuters story on it -- do go read it all:
. . . .Pfizer has so far received $60 million in upfront and milestone payments and will be eligible for additional payments associated with clinical, regulatory and commercial milestones.Do stay tuned. UPDATED: Gratifyingly, it would seem that the take of the well-regarded maven, Ed Silverman, over at Pharmalot, on this news, agrees with mine -- and independently, so -- I might add. So, I'd call that definitive.
Merck and Pfizer will share potential revenue and certain costs on a 60/40 percent basis, the companies said.
Merck and Pfizer will collaborate on the development and marketing of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin, a common diabetes treatment, and Merck's Januvia tablets. . . .